3D Angiogenesis Assay for Heart Study

Information

  • Research Project
  • 7746745
  • ApplicationId
    7746745
  • Core Project Number
    R43HL093897
  • Full Project Number
    1R43HL093897-01A1
  • Serial Number
    93897
  • FOA Number
    PA-08-050
  • Sub Project Id
  • Project Start Date
    9/10/2009 - 15 years ago
  • Project End Date
    3/31/2011 - 13 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    9/10/2009 - 15 years ago
  • Budget End Date
    3/31/2011 - 13 years ago
  • Fiscal Year
    2009
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/10/2009 - 15 years ago
Organizations

3D Angiogenesis Assay for Heart Study

DESCRIPTION (provided by applicant): Angiogenesis is the growth of new blood vessels from the existing vasculature. It is implicated in many diseases and disciplines, including heart disease where it plays an important role in repair of ischemic tissue following myocardial infarction. Heart disease is the second leading cause of death in the United States. Hope for effective angiogenesis therapies in ischemic heart disease has been dampened by a series of mostly disappointing clinical trials. Despite the importance of angiogenesis, there is a lack of effective angiogenesis assays and this is hampering progress in developing angiogenic therapeutics. While there exist a number of vitro and in vivo screening assays which can provide information about specific, narrow aspects of angiogenesis, it is often very difficult to interpret how the results of these assays pertain to the physiological relevant 3D microscopic tissue level where angiogenesis actually manifests. In particular, there is a conspicuous lack of assays that provide direct information about capillary morphology and function in situ even though this is ultimately the most important aspect of angiogenesis. This proposal is for the development of a high throughput 3D angiogenesis assay at the in situ tissue level. It accomplishes this by employing high speed 3D microscopic imaging, multispectral detection, advanced tissue labeling protocols, and software for high content image analysis. As a first application we will apply this to study the angiogenic response to fibroblast growth factor (bFGF) in myocardial ischemia. We believe this assay will become a valuable tool for basic researchers and provide crucial information in the late drug development process to pharmaceutical companies on whether to continue the development of a drug candidate. PUBLIC HEALTH RELEVANCE: This proposal describes the development of a new angiogenesis assay which we apply to the study of heart disease. Its key innovations are highly detailed 3D images of the microvascular, and the ability to this back to tissue physiology, composition and biochemical state. It has the strong potential to reduce the cost of doing angiogenesis assays in animal models as well as offer high physiological relevance and advance the use of angiogenesis therapies for the treatment of heart disease.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    165646
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:165646\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TISSUEVISION, INC.
  • Organization Department
  • Organization DUNS
    606771918
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021393233
  • Organization District
    UNITED STATES